Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer.
The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.
The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
|TTI-621||Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)||Phase 1a/b updated data released at ASH 2017 – 5/18 objective response rate.|
|TTI-621||Solid tumors||Phase 1a/b trial ongoing.|
|TTI-621||Sézary syndrome||Phase 1a/b updated data released at ASH 2017.|
|TTI-622||Refractory lymphoma or multiple myeloma||Phase 1a/b dosing has been initiated – June 14, 2018.|